In hemophilia A, emicizumab cuts bleeding; plasma-derived factor VIII less likely to trigger antibodies

Patients with severe hemophilia A treated with plasma-derived factor VIII, as compared with recombinant factor VIII, had a lower risk of developing neutralizing antibodies, based on a recent report...
Source: Pediatric News - Category: Journals (General) Source Type: news